Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions

Abstract With the recent approval of disease‐modifying treatments for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) by the United States Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), European Medicine Agency's Committee for Medici...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Jamie L. Hamilton, Rebecca L. M. Fuller, Noopur Modi, Cristina Sampaio
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2025-07-01
Serier:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Fag:	clinically meaningful benefit cognitive impairment dementia disease‐modifying treatments minimally clinically important difference
Online adgang:	https://doi.org/10.1002/trc2.70138
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!